Wire · opportunities
FDA Approves Atezolizumab Plus Chemo for Stage 3 dMMR Colon Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 October 2026 · Fusion42 review
The FDA approved atezolizumab in combination with FOLFOX chemotherapy for adjuvant treatment of stage 3 mismatch repair–deficient colon cancer, based on the ATOMIC trial that demonstrated a 50% reduction in risk of recurrence or death. The approval also includes a subcutaneous formulation for pediatric patients 12 years and older.
This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 8 Oct 2026 and 9 Oct 2026.
◆ ◆ The Wire takeaway
You must update your oncology protocols immediately as atezolizumab plus chemotherapy is now the FDA-approved standard for stage 3 dMMR colon cancer, opening clinical opportunities and patient conversations around immunotherapy. Immune side effects rise, so prepare your care pathways to manage increased toxicity aggressively.
◆ Coverage
4 sources · first reported 8 Oct 2026 · latest 9 Oct 2026
◆ Related on Wire
◆ Topics